- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
The United States National Institutes of Health will conduct a large Phase 3 clinical trial investigating if any current prescription or over-the-counter medications can be used to treat non-hospitalised COVID-19 patients. The study, called ACTIV-6, will evaluate up to seven drugs which are currently approved for other conditions. Around 13,500 people aged 30 years and above who have tested positive for COVID-19 with mild-moderate symptoms will be enrolled. Focus will be placed on people from minority, rural and other communities heavily affected by COVID-19 but far from major medical centres. Enrollment is likely to begin in the coming weeks, after the list of possible drug treatments is finalized. The study will look at changes in short and long terms symptoms as well as numbers of hospitalisations and deaths for the various treatment groups.
Additional data provided by
English
Japanese
